Behgam Nader, Rahimi Esbo Sobhan, Nikbakht Hossein-Ali, Rezghi Maedeh, Memariani Zahra
Student Research Committee, Babol University of Medical Sciences, Babol, Iran.
Department of Medical Sciences Education Development, Education Development Center, Babol University of Medical Sciences, Babol, Iran.
Daru. 2025 Mar 20;33(1):16. doi: 10.1007/s40199-025-00558-x.
OBJECTIVES: Rosa damascena Mill. has been studied in clinical trials for the treatment of diverse gastrointestinal diseases. The aim of this study is to conduct a systematic review and meta-analysis of clinical trials using R. damascena in the management of gastrointestinal disorders. EVIDENCE ACQUISITION: PubMed, Web of Science, Embase, Scopus, and Google Scholar were searched up to Jun 30, 2024. Clinical trials utilizing R. damascena for gastrointestinal disorders were included in the study. The study protocol was registered in PROSPERO (CRD42024519644). The main keywords for the search were R. damascena, gastrointestinal, digestive system, and clinical trials. The Cochrane RoB 2.0 tool was employed for quality assessment of randomized controlled trials. A summary of intervention effects for each study was provided by calculating standardized mean differences and accompanying 95% confidence intervals using a random-effects model. Weighted mean differences and heterogeneity between studies were assessed using Hedges's method and Cochran's Q test, respectively. Additionally, the risk ratio (RR) index was utilized to investigate the effect of R. damascena. RESULTS: Thirteen studies were included for systematic review. The results showed that the use of R. damascena significantly improves the Quality of life (SMD: 0.84, CI95%: 0.03 to 1.65, P = 0.041) and mean defecation frequency per week (SMD: 0.86, CI95%:0.14 to 1.58, P = 0.018) in patients with constipation. However, no improvement was observed in the Bristol stool form scale in patients with constipation, and this relationship was not statistically significant either (SMD: -1.34, CI95%: -4.39 to 1.71, P = 0.388). Also, the rate of incomplete evacuation significantly improved in patients with constipation (RR: 0.78, CI95%: 0.63 to 0.94, P = 0.035). CONCLUSION: Based on the results of this study, R. damascena could have promising effects on symptoms of patients with functional constipation and their quality of life. Future studies should focus on standardizing methodologies, exploring different dosage levels, and investigating its effects on a wider range of gastrointestinal conditions.
目的：大马士革蔷薇已在治疗多种胃肠道疾病的临床试验中得到研究。本研究的目的是对使用大马士革蔷薇治疗胃肠道疾病的临床试验进行系统评价和荟萃分析。 证据获取：截至2024年6月30日，检索了PubMed、科学网、Embase、Scopus和谷歌学术。本研究纳入了使用大马士革蔷薇治疗胃肠道疾病的临床试验。研究方案已在国际前瞻性系统评价注册库（PROSPERO，注册号：CRD42024519644）登记。检索的主要关键词为大马士革蔷薇、胃肠道、消化系统和临床试验。采用Cochrane偏倚风险2.0工具对随机对照试验进行质量评估。使用随机效应模型计算标准化均数差及相应的95%置信区间，以提供每项研究的干预效果总结。分别采用Hedges方法和Cochrane Q检验评估研究间的加权均数差和异质性。此外，利用风险比（RR）指标研究大马士革蔷薇的作用。 结果：纳入13项研究进行系统评价。结果显示，使用大马士革蔷薇可显著改善便秘患者的生活质量（标准化均数差：0.84，95%置信区间：0.03至1.65，P = 0.041）和每周平均排便频率（标准化均数差：0.86，95%置信区间：0.14至1.58，P = 0.018）。然而，便秘患者的布里斯托大便分类法评分未得到改善，且这种关系也无统计学意义（标准化均数差：-1.34，95%置信区间：-4.39至1.71，P = 0.388）。此外，便秘患者的排便不尽率显著改善（RR：0.78，95%置信区间：0.63至0.94，P = 0.035）。 结论：基于本研究结果，大马士革蔷薇可能对功能性便秘患者的症状及其生活质量有良好效果。未来的研究应侧重于规范方法、探索不同剂量水平，并研究其对更广泛胃肠道疾病的影响。
Cochrane Database Syst Rev. 2024-10-29
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2016-8-17
Cochrane Database Syst Rev. 2017-12-22
Cochrane Database Syst Rev. 2020-1-9
Cochrane Database Syst Rev. 2012-7-11
Cochrane Database Syst Rev. 2018-6-8
Cochrane Database Syst Rev. 2016-3-31
Cochrane Database Syst Rev. 2016-11-24
Complement Ther Clin Pract. 2021-5
J Pharm Pharmacol. 2019-11-11
Zotero 插件